Share Price and Basic Stock Data
Last Updated: October 29, 2025, 9:34 pm
| PEG Ratio | 6.66 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Neuland Laboratories Ltd, operating in the pharmaceuticals sector, recorded a market capitalization of ₹20,194 Cr, with a share price of ₹15,740. The company reported significant revenue growth, with sales rising from ₹951 Cr in FY 2022 to ₹1,191 Cr in FY 2023, and projected revenue for FY 2024 standing at ₹1,559 Cr. Quarterly sales figures indicate a strong upward trend, with revenues peaking at ₹418 Cr in September 2023, despite a slight decline to ₹393 Cr by December 2023. The trailing twelve months (TTM) revenue was ₹1,330 Cr, indicating robust operational performance. The company has consistently improved its operational capacity, as evidenced by the rise in quarterly sales, which reflects a growing demand for its pharmaceutical products. This growth trajectory positions Neuland favorably within the competitive landscape of the Indian pharmaceutical industry, which is characterized by an increasing need for generic medicines and active pharmaceutical ingredients (APIs). The company’s ability to navigate market challenges and capitalize on opportunities is crucial for sustaining this growth momentum.
Profitability and Efficiency Metrics
Neuland Laboratories demonstrated impressive profitability metrics, with a reported net profit of ₹176 Cr for the TTM period, reflecting a net profit margin of 13.23%. The company’s operating profit margin (OPM) stood at 12% for the current period, showcasing its ability to manage expenses effectively relative to its sales. Notably, the OPM peaked at 33% in September 2023, indicating strong operational efficiency during this quarter. Additionally, the company achieved a return on equity (ROE) of 14.8% and return on capital employed (ROCE) of 18.7%, both of which are commendable compared to typical sector ranges. The interest coverage ratio (ICR) reported at 41.43x suggests that Neuland can comfortably meet its interest obligations, reflecting financial stability. However, the cash conversion cycle (CCC) of 160 days indicates a need for improvement in working capital management, particularly in reducing the time taken to convert inventory into cash. Overall, Neuland’s profitability and efficiency metrics highlight its operational strengths while also identifying areas for potential enhancement.
Balance Sheet Strength and Financial Ratios
Neuland Laboratories maintained a robust balance sheet with total assets of ₹2,180 Cr and reserves amounting to ₹1,512 Cr as of March 2025. The company’s borrowings were relatively low at ₹157 Cr, translating to a total debt-to-equity ratio of just 0.08, which is favorable compared to industry norms and indicates a conservative approach to leveraging. The current ratio of 2.45 and quick ratio of 1.62 demonstrate strong liquidity, suggesting that the company is well-positioned to meet its short-term obligations. Furthermore, Neuland’s price-to-book value (P/BV) ratio stood at 10.22x, indicating that the market currently values the company significantly above its book value, reflecting investor confidence in its growth prospects. Other financial ratios, such as the asset turnover ratio of 0.73%, signify efficient utilization of assets in generating revenue. However, the high price-to-earnings (P/E) ratio of 153 suggests that the stock may be overvalued relative to earnings, warranting caution for potential investors. Overall, Neuland’s balance sheet strength and financial ratios reflect a solid foundation, although high valuation metrics may pose risks for investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Neuland Laboratories indicates a diverse investor base, with promoters holding 32.67% of the company, while foreign institutional investors (FIIs) accounted for 21.69% and domestic institutional investors (DIIs) held 11.57%. The public ownership stands at 33.67%, demonstrating a balanced distribution among various stakeholders. The gradual decline in promoter shareholding from 36.22% in September 2022 to 32.67% in March 2025 could raise concerns about insider confidence, although the overall ownership structure remains stable. The recent increase in FII holdings from 17.68% in September 2022 to 21.69% in March 2025 suggests growing confidence among international investors, likely driven by the company’s strong financial performance and growth potential. Additionally, the number of shareholders increased significantly to 42,419 by June 2025, reflecting heightened public interest in the stock. This diverse ownership structure, combined with increasing institutional interest, indicates a solid foundation for Neuland’s future growth and investor confidence.
Outlook, Risks, and Final Insight
Neuland Laboratories is well-positioned for continued growth, bolstered by strong revenue trends and solid profitability metrics. However, the company faces several risks that could impact its future performance. These include the high P/E ratio of 153, which may indicate overvaluation, potentially leading to volatility if earnings do not meet market expectations. Additionally, the cash conversion cycle of 160 days suggests inefficiencies in working capital management that need to be addressed to improve liquidity. Furthermore, the pharmaceutical sector is highly regulated, and any changes in regulatory policies could affect operations. On the positive side, Neuland’s strong balance sheet, coupled with low debt levels and a diverse shareholder base, provides a cushion against market fluctuations. Should the company enhance its operational efficiencies and maintain its growth trajectory, it could emerge as a leader in the pharmaceuticals sector. Investors should weigh these strengths against the identified risks while considering their investment decisions.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Neuland Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 145 Cr. | 116 | 247/84.3 | 33.1 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.80 Cr. | 1.99 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,983 Cr. | 460 | 479/192 | 112 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 35.6 Cr. | 48.0 | 94.9/37.2 | 8.73 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 32.2 Cr. | 22.0 | 29.1/17.0 | 33.6 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,879.00 Cr | 1,180.37 | 50.35 | 194.36 | 0.33% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 221 | 294 | 269 | 407 | 363 | 418 | 393 | 385 | 440 | 311 | 398 | 328 | 293 |
| Expenses | 193 | 224 | 215 | 287 | 266 | 280 | 272 | 278 | 316 | 249 | 311 | 277 | 258 |
| Operating Profit | 29 | 69 | 54 | 120 | 97 | 137 | 121 | 107 | 123 | 62 | 87 | 51 | 34 |
| OPM % | 13% | 24% | 20% | 29% | 27% | 33% | 31% | 28% | 28% | 20% | 22% | 16% | 12% |
| Other Income | 1 | 0 | 1 | 8 | 2 | 3 | 2 | 5 | 25 | 4 | 60 | 7 | 8 |
| Interest | 3 | 3 | 3 | 4 | 2 | 4 | 4 | 4 | 3 | 1 | 2 | 2 | 5 |
| Depreciation | 13 | 13 | 13 | 13 | 14 | 15 | 15 | 16 | 16 | 16 | 16 | 17 | 20 |
| Profit before tax | 13 | 53 | 39 | 110 | 83 | 122 | 104 | 92 | 130 | 49 | 128 | 39 | 18 |
| Tax % | 26% | 28% | 22% | 23% | 26% | 27% | 22% | 27% | 25% | 34% | 20% | 29% | 21% |
| Net Profit | 10 | 38 | 31 | 85 | 62 | 89 | 81 | 68 | 98 | 33 | 102 | 28 | 14 |
| EPS in Rs | 7.77 | 29.98 | 23.81 | 65.89 | 48.23 | 69.56 | 63.44 | 52.66 | 76.28 | 25.60 | 79.18 | 21.68 | 10.83 |
Last Updated: August 1, 2025, 4:25 pm
Below is a detailed analysis of the quarterly data for Neuland Laboratories Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 293.00 Cr.. The value appears to be declining and may need further review. It has decreased from 328.00 Cr. (Mar 2025) to 293.00 Cr., marking a decrease of 35.00 Cr..
- For Expenses, as of Jun 2025, the value is 258.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 277.00 Cr. (Mar 2025) to 258.00 Cr., marking a decrease of 19.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 34.00 Cr.. The value appears to be declining and may need further review. It has decreased from 51.00 Cr. (Mar 2025) to 34.00 Cr., marking a decrease of 17.00 Cr..
- For OPM %, as of Jun 2025, the value is 12.00%. The value appears to be declining and may need further review. It has decreased from 16.00% (Mar 2025) to 12.00%, marking a decrease of 4.00%.
- For Other Income, as of Jun 2025, the value is 8.00 Cr.. The value appears strong and on an upward trend. It has increased from 7.00 Cr. (Mar 2025) to 8.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.00 Cr. (Mar 2025) to 5.00 Cr., marking an increase of 3.00 Cr..
- For Depreciation, as of Jun 2025, the value is 20.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 3.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 18.00 Cr.. The value appears to be declining and may need further review. It has decreased from 39.00 Cr. (Mar 2025) to 18.00 Cr., marking a decrease of 21.00 Cr..
- For Tax %, as of Jun 2025, the value is 21.00%. The value appears to be improving (decreasing) as expected. It has decreased from 29.00% (Mar 2025) to 21.00%, marking a decrease of 8.00%.
- For Net Profit, as of Jun 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 14.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 10.83. The value appears to be declining and may need further review. It has decreased from 21.68 (Mar 2025) to 10.83, marking a decrease of 10.85.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:46 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 466 | 469 | 510 | 579 | 527 | 667 | 763 | 937 | 951 | 1,191 | 1,559 | 1,477 | 1,330 |
| Expenses | 395 | 402 | 430 | 472 | 477 | 608 | 661 | 790 | 807 | 918 | 1,096 | 1,146 | 1,096 |
| Operating Profit | 71 | 67 | 80 | 106 | 51 | 58 | 102 | 147 | 144 | 273 | 463 | 331 | 234 |
| OPM % | 15% | 14% | 16% | 18% | 10% | 9% | 13% | 16% | 15% | 23% | 30% | 22% | 18% |
| Other Income | 3 | 0 | 2 | 1 | 4 | 3 | 4 | 16 | 0 | 9 | 12 | 90 | 79 |
| Interest | 25 | 27 | 24 | 21 | 19 | 16 | 22 | 18 | 14 | 13 | 14 | 8 | 10 |
| Depreciation | 15 | 15 | 16 | 19 | 22 | 26 | 31 | 40 | 49 | 53 | 60 | 66 | 69 |
| Profit before tax | 35 | 25 | 42 | 67 | 14 | 20 | 53 | 105 | 82 | 216 | 401 | 346 | 234 |
| Tax % | 23% | 36% | 36% | 30% | 13% | 19% | 69% | 23% | 22% | 24% | 25% | 25% | |
| Net Profit | 27 | 16 | 27 | 47 | 12 | 16 | 16 | 81 | 64 | 164 | 300 | 260 | 176 |
| EPS in Rs | 30.12 | 17.96 | 30.75 | 52.74 | 13.57 | 12.81 | 12.63 | 62.85 | 49.74 | 127.45 | 233.89 | 202.74 | 137.29 |
| Dividend Payout % | 9% | 8% | 7% | 0% | 0% | 0% | 16% | 8% | 10% | 8% | 6% | 6% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -40.74% | 68.75% | 74.07% | -74.47% | 33.33% | 0.00% | 406.25% | -20.99% | 156.25% | 82.93% | -13.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | 109.49% | 5.32% | -148.54% | 107.80% | -33.33% | 406.25% | -427.24% | 177.24% | -73.32% | -96.26% |
Neuland Laboratories Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 14% |
| 3 Years: | 16% |
| TTM: | -19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 67% |
| 3 Years: | 47% |
| TTM: | -59% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 38% |
| 5 Years: | 71% |
| 3 Years: | 130% |
| 1 Year: | 14% |
| Return on Equity | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | 16% |
| 3 Years: | 19% |
| Last Year: | 15% |
Last Updated: September 5, 2025, 11:40 am
Balance Sheet
Last Updated: July 25, 2025, 2:41 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 9 | 9 | 9 | 9 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 116 | 152 | 178 | 537 | 549 | 686 | 697 | 774 | 828 | 981 | 1,270 | 1,512 |
| Borrowings | 190 | 188 | 182 | 192 | 319 | 231 | 264 | 182 | 241 | 128 | 95 | 157 |
| Other Liabilities | 169 | 162 | 155 | 148 | 194 | 200 | 257 | 356 | 302 | 457 | 454 | 498 |
| Total Liabilities | 483 | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,833 | 2,180 |
| Fixed Assets | 131 | 123 | 139 | 466 | 475 | 542 | 653 | 716 | 767 | 758 | 824 | 955 |
| CWIP | 35 | 41 | 40 | 20 | 126 | 104 | 24 | 17 | 20 | 41 | 46 | 48 |
| Investments | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 7 | 4 | 1 | 1 | 109 |
| Other Assets | 311 | 340 | 337 | 393 | 463 | 476 | 547 | 585 | 592 | 781 | 962 | 1,068 |
| Total Assets | 483 | 512 | 524 | 886 | 1,071 | 1,130 | 1,231 | 1,325 | 1,383 | 1,580 | 1,833 | 2,180 |
Below is a detailed analysis of the balance sheet data for Neuland Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 13.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,512.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,270.00 Cr. (Mar 2024) to 1,512.00 Cr., marking an increase of 242.00 Cr..
- For Borrowings, as of Mar 2025, the value is 157.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 95.00 Cr. (Mar 2024) to 157.00 Cr., marking an increase of 62.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 498.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 454.00 Cr. (Mar 2024) to 498.00 Cr., marking an increase of 44.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,180.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,833.00 Cr. (Mar 2024) to 2,180.00 Cr., marking an increase of 347.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 955.00 Cr.. The value appears strong and on an upward trend. It has increased from 824.00 Cr. (Mar 2024) to 955.00 Cr., marking an increase of 131.00 Cr..
- For CWIP, as of Mar 2025, the value is 48.00 Cr.. The value appears strong and on an upward trend. It has increased from 46.00 Cr. (Mar 2024) to 48.00 Cr., marking an increase of 2.00 Cr..
- For Investments, as of Mar 2025, the value is 109.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2024) to 109.00 Cr., marking an increase of 108.00 Cr..
- For Other Assets, as of Mar 2025, the value is 1,068.00 Cr.. The value appears strong and on an upward trend. It has increased from 962.00 Cr. (Mar 2024) to 1,068.00 Cr., marking an increase of 106.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,180.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,833.00 Cr. (Mar 2024) to 2,180.00 Cr., marking an increase of 347.00 Cr..
Notably, the Reserves (1,512.00 Cr.) exceed the Borrowings (157.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -119.00 | -121.00 | -102.00 | -86.00 | -268.00 | -173.00 | -162.00 | -35.00 | -97.00 | 145.00 | 368.00 | 174.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 93 | 100 | 85 | 114 | 134 | 90 | 91 | 85 | 90 | 111 | 87 | 78 |
| Inventory Days | 138 | 170 | 182 | 186 | 266 | 191 | 209 | 205 | 227 | 211 | 220 | 238 |
| Days Payable | 139 | 167 | 121 | 118 | 189 | 118 | 110 | 126 | 100 | 129 | 121 | 156 |
| Cash Conversion Cycle | 92 | 103 | 147 | 182 | 211 | 162 | 190 | 164 | 216 | 193 | 187 | 160 |
| Working Capital Days | -21 | 11 | 26 | 44 | 38 | 44 | 49 | 60 | 74 | 81 | 88 | 76 |
| ROCE % | 19% | 16% | 18% | 16% | 4% | 4% | 8% | 11% | 10% | 21% | 33% | 19% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 116,449 | 0.57 | 63.66 | 116,449 | 2025-04-22 17:25:25 | 0% |
| WhiteOak Capital Flexi Cap Fund | 57,756 | 1.19 | 31.57 | 57,756 | 2025-04-22 17:25:25 | 0% |
| WhiteOak Capital Mid Cap Fund | 27,505 | 1.15 | 15.04 | 27,505 | 2025-04-22 17:25:25 | 0% |
| WhiteOak Capital Multi Cap Fund | 11,091 | 1.17 | 6.06 | 11,091 | 2025-04-22 17:25:25 | 0% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 9,088 | 0.87 | 4.97 | 9,088 | 2025-04-22 17:25:25 | 0% |
| WhiteOak Capital Balanced Advantage Fund | 7,532 | 0.56 | 4.12 | 7,532 | 2025-04-22 17:25:25 | 0% |
| WhiteOak Capital ELSS Tax Saver Fund | 2,483 | 1.23 | 1.36 | 2,483 | 2025-04-22 17:25:25 | 0% |
| WhiteOak Capital Large Cap Fund | 2,111 | 0.31 | 1.15 | 2,111 | 2025-04-22 17:25:25 | 0% |
| WhiteOak Capital Multi Asset Allocation Fund | 1,882 | 0.42 | 1.03 | 1,882 | 2025-04-22 17:25:25 | 0% |
| WhiteOak Capital Balanced Hybrid Fund | 762 | 0.55 | 0.42 | 762 | 2025-04-22 17:25:25 | 0% |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 202.74 | 233.89 | 127.45 | 49.74 | 62.85 |
| Diluted EPS (Rs.) | 202.74 | 233.89 | 127.45 | 49.74 | 62.85 |
| Cash EPS (Rs.) | 252.44 | 278.89 | 167.66 | 87.49 | 93.26 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 1181.32 | 993.65 | 769.94 | 650.88 | 608.98 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 1181.97 | 994.31 | 770.59 | 651.52 | 609.63 |
| Revenue From Operations / Share (Rs.) | 1144.79 | 1208.16 | 923.37 | 737.24 | 726.26 |
| PBDIT / Share (Rs.) | 266.48 | 368.31 | 218.28 | 112.16 | 126.29 |
| PBIT / Share (Rs.) | 215.67 | 322.03 | 177.37 | 74.15 | 95.52 |
| PBT / Share (Rs.) | 268.46 | 311.18 | 167.24 | 63.69 | 81.65 |
| Net Profit / Share (Rs.) | 201.63 | 232.61 | 126.75 | 49.47 | 62.50 |
| NP After MI And SOA / Share (Rs.) | 201.63 | 232.61 | 126.75 | 49.47 | 62.50 |
| PBDIT Margin (%) | 23.27 | 30.48 | 23.63 | 15.21 | 17.38 |
| PBIT Margin (%) | 18.83 | 26.65 | 19.20 | 10.05 | 13.15 |
| PBT Margin (%) | 23.45 | 25.75 | 18.11 | 8.63 | 11.24 |
| Net Profit Margin (%) | 17.61 | 19.25 | 13.72 | 6.71 | 8.60 |
| NP After MI And SOA Margin (%) | 17.61 | 19.25 | 13.72 | 6.71 | 8.60 |
| Return on Networth / Equity (%) | 17.06 | 23.40 | 16.46 | 7.60 | 10.26 |
| Return on Capital Employeed (%) | 16.23 | 29.57 | 20.05 | 9.37 | 12.88 |
| Return On Assets (%) | 11.93 | 16.37 | 10.35 | 4.61 | 6.08 |
| Long Term Debt / Equity (X) | 0.05 | 0.03 | 0.07 | 0.12 | 0.11 |
| Total Debt / Equity (X) | 0.08 | 0.06 | 0.12 | 0.27 | 0.18 |
| Asset Turnover Ratio (%) | 0.73 | 0.91 | 0.80 | 0.70 | 0.73 |
| Current Ratio (X) | 2.45 | 2.15 | 1.73 | 1.60 | 1.49 |
| Quick Ratio (X) | 1.62 | 1.33 | 1.10 | 0.87 | 0.81 |
| Inventory Turnover Ratio (X) | 1.56 | 2.01 | 1.79 | 1.71 | 1.88 |
| Dividend Payout Ratio (NP) (%) | 6.90 | 4.27 | 3.92 | 6.03 | 3.18 |
| Dividend Payout Ratio (CP) (%) | 5.51 | 3.56 | 2.96 | 3.41 | 2.13 |
| Earning Retention Ratio (%) | 93.10 | 95.73 | 96.08 | 93.97 | 96.82 |
| Cash Earning Retention Ratio (%) | 94.49 | 96.44 | 97.04 | 96.59 | 97.87 |
| Interest Coverage Ratio (X) | 41.43 | 33.94 | 21.55 | 10.72 | 9.10 |
| Interest Coverage Ratio (Post Tax) (X) | 23.14 | 22.44 | 13.51 | 5.73 | 5.50 |
| Enterprise Value (Cr.) | 15457.06 | 8068.90 | 2383.79 | 1534.95 | 2819.28 |
| EV / Net Operating Revenue (X) | 10.47 | 5.18 | 2.00 | 1.61 | 3.01 |
| EV / EBITDA (X) | 44.96 | 16.98 | 8.47 | 10.61 | 17.31 |
| MarketCap / Net Operating Revenue (X) | 10.55 | 5.20 | 1.95 | 1.39 | 2.87 |
| Retention Ratios (%) | 93.09 | 95.72 | 96.07 | 93.96 | 96.81 |
| Price / BV (X) | 10.22 | 6.32 | 2.34 | 1.58 | 3.43 |
| Price / Net Operating Revenue (X) | 10.55 | 5.20 | 1.95 | 1.39 | 2.87 |
| EarningsYield | 0.01 | 0.03 | 0.07 | 0.04 | 0.02 |
After reviewing the key financial ratios for Neuland Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 202.74. This value is within the healthy range. It has decreased from 233.89 (Mar 24) to 202.74, marking a decrease of 31.15.
- For Diluted EPS (Rs.), as of Mar 25, the value is 202.74. This value is within the healthy range. It has decreased from 233.89 (Mar 24) to 202.74, marking a decrease of 31.15.
- For Cash EPS (Rs.), as of Mar 25, the value is 252.44. This value is within the healthy range. It has decreased from 278.89 (Mar 24) to 252.44, marking a decrease of 26.45.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,181.32. It has increased from 993.65 (Mar 24) to 1,181.32, marking an increase of 187.67.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 1,181.97. It has increased from 994.31 (Mar 24) to 1,181.97, marking an increase of 187.66.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,144.79. It has decreased from 1,208.16 (Mar 24) to 1,144.79, marking a decrease of 63.37.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 266.48. This value is within the healthy range. It has decreased from 368.31 (Mar 24) to 266.48, marking a decrease of 101.83.
- For PBIT / Share (Rs.), as of Mar 25, the value is 215.67. This value is within the healthy range. It has decreased from 322.03 (Mar 24) to 215.67, marking a decrease of 106.36.
- For PBT / Share (Rs.), as of Mar 25, the value is 268.46. This value is within the healthy range. It has decreased from 311.18 (Mar 24) to 268.46, marking a decrease of 42.72.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 201.63. This value is within the healthy range. It has decreased from 232.61 (Mar 24) to 201.63, marking a decrease of 30.98.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 201.63. This value is within the healthy range. It has decreased from 232.61 (Mar 24) to 201.63, marking a decrease of 30.98.
- For PBDIT Margin (%), as of Mar 25, the value is 23.27. This value is within the healthy range. It has decreased from 30.48 (Mar 24) to 23.27, marking a decrease of 7.21.
- For PBIT Margin (%), as of Mar 25, the value is 18.83. This value is within the healthy range. It has decreased from 26.65 (Mar 24) to 18.83, marking a decrease of 7.82.
- For PBT Margin (%), as of Mar 25, the value is 23.45. This value is within the healthy range. It has decreased from 25.75 (Mar 24) to 23.45, marking a decrease of 2.30.
- For Net Profit Margin (%), as of Mar 25, the value is 17.61. This value exceeds the healthy maximum of 10. It has decreased from 19.25 (Mar 24) to 17.61, marking a decrease of 1.64.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 17.61. This value is within the healthy range. It has decreased from 19.25 (Mar 24) to 17.61, marking a decrease of 1.64.
- For Return on Networth / Equity (%), as of Mar 25, the value is 17.06. This value is within the healthy range. It has decreased from 23.40 (Mar 24) to 17.06, marking a decrease of 6.34.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.23. This value is within the healthy range. It has decreased from 29.57 (Mar 24) to 16.23, marking a decrease of 13.34.
- For Return On Assets (%), as of Mar 25, the value is 11.93. This value is within the healthy range. It has decreased from 16.37 (Mar 24) to 11.93, marking a decrease of 4.44.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.05, marking an increase of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.08. This value is within the healthy range. It has increased from 0.06 (Mar 24) to 0.08, marking an increase of 0.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.73. It has decreased from 0.91 (Mar 24) to 0.73, marking a decrease of 0.18.
- For Current Ratio (X), as of Mar 25, the value is 2.45. This value is within the healthy range. It has increased from 2.15 (Mar 24) to 2.45, marking an increase of 0.30.
- For Quick Ratio (X), as of Mar 25, the value is 1.62. This value is within the healthy range. It has increased from 1.33 (Mar 24) to 1.62, marking an increase of 0.29.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.56. This value is below the healthy minimum of 4. It has decreased from 2.01 (Mar 24) to 1.56, marking a decrease of 0.45.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 6.90. This value is below the healthy minimum of 20. It has increased from 4.27 (Mar 24) to 6.90, marking an increase of 2.63.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 5.51. This value is below the healthy minimum of 20. It has increased from 3.56 (Mar 24) to 5.51, marking an increase of 1.95.
- For Earning Retention Ratio (%), as of Mar 25, the value is 93.10. This value exceeds the healthy maximum of 70. It has decreased from 95.73 (Mar 24) to 93.10, marking a decrease of 2.63.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 94.49. This value exceeds the healthy maximum of 70. It has decreased from 96.44 (Mar 24) to 94.49, marking a decrease of 1.95.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 41.43. This value is within the healthy range. It has increased from 33.94 (Mar 24) to 41.43, marking an increase of 7.49.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 23.14. This value is within the healthy range. It has increased from 22.44 (Mar 24) to 23.14, marking an increase of 0.70.
- For Enterprise Value (Cr.), as of Mar 25, the value is 15,457.06. It has increased from 8,068.90 (Mar 24) to 15,457.06, marking an increase of 7,388.16.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 10.47. This value exceeds the healthy maximum of 3. It has increased from 5.18 (Mar 24) to 10.47, marking an increase of 5.29.
- For EV / EBITDA (X), as of Mar 25, the value is 44.96. This value exceeds the healthy maximum of 15. It has increased from 16.98 (Mar 24) to 44.96, marking an increase of 27.98.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 10.55. This value exceeds the healthy maximum of 3. It has increased from 5.20 (Mar 24) to 10.55, marking an increase of 5.35.
- For Retention Ratios (%), as of Mar 25, the value is 93.09. This value exceeds the healthy maximum of 70. It has decreased from 95.72 (Mar 24) to 93.09, marking a decrease of 2.63.
- For Price / BV (X), as of Mar 25, the value is 10.22. This value exceeds the healthy maximum of 3. It has increased from 6.32 (Mar 24) to 10.22, marking an increase of 3.90.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 10.55. This value exceeds the healthy maximum of 3. It has increased from 5.20 (Mar 24) to 10.55, marking an increase of 5.35.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.01, marking a decrease of 0.02.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Neuland Laboratories Ltd:
- Net Profit Margin: 17.61%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.23% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 17.06% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 23.14
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.62
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 150 (Industry average Stock P/E: 50.35)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.08
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 17.61%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 11th Floor (5th Office Level), Phoenix IVY Building, Hyderabad Telangana 500033 | ir@neulandlabs.com http://www.neulandlabs.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Davuluri Rama Mohan Rao | Executive Chairman |
| Mr. Davuluri Sucheth Rao | Vice Chairman & CEO |
| Mr. Davuluri Saharsh Rao | Vice Chairman & Mng.Director |
| Dr. Christopher M Cimarusti | Non Executive Director |
| Mr. Homi Rustum Khusrokhan | Ind. Non-Executive Director |
| Mr. Prasad Raghava Menon | Ind. Non-Executive Director |
| Mr. Sugata Sircar | Ind. Non-Executive Director |
| Ms. Pallavi Joshi Bakhru | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Neuland Laboratories Ltd?
Neuland Laboratories Ltd's intrinsic value (as of 29 October 2025) is 21115.76 which is 37.06% higher the current market price of 15,406.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 19,764 Cr. market cap, FY2025-2026 high/low of 18,100/10,060, reserves of ₹1,512 Cr, and liabilities of 2,180 Cr.
What is the Market Cap of Neuland Laboratories Ltd?
The Market Cap of Neuland Laboratories Ltd is 19,764 Cr..
What is the current Stock Price of Neuland Laboratories Ltd as on 29 October 2025?
The current stock price of Neuland Laboratories Ltd as on 29 October 2025 is 15,406.
What is the High / Low of Neuland Laboratories Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Neuland Laboratories Ltd stocks is 18,100/10,060.
What is the Stock P/E of Neuland Laboratories Ltd?
The Stock P/E of Neuland Laboratories Ltd is 150.
What is the Book Value of Neuland Laboratories Ltd?
The Book Value of Neuland Laboratories Ltd is 1,188.
What is the Dividend Yield of Neuland Laboratories Ltd?
The Dividend Yield of Neuland Laboratories Ltd is 0.08 %.
What is the ROCE of Neuland Laboratories Ltd?
The ROCE of Neuland Laboratories Ltd is 18.7 %.
What is the ROE of Neuland Laboratories Ltd?
The ROE of Neuland Laboratories Ltd is 14.8 %.
What is the Face Value of Neuland Laboratories Ltd?
The Face Value of Neuland Laboratories Ltd is 10.0.